In the last trading session, 7.83 million Better Therapeutics Inc (NASDAQ:BTTX) shares changed hands as the company’s beta touched 2.31. With the company’s per share price at $0.21 changed hands at $0.04 or 23.60% during last session, the market valuation stood at $9.95M. BTTX’s last price was a discount, traded about -666.67% off its 52-week high of $1.61. The share price had its 52-week low at $0.14, which suggests the last value was 33.33% up since then. When we look at Better Therapeutics Inc’s average trading volume, we note the 10-day average is 1.42 million shares, with the 3-month average coming to 1.60 million.
Analysts gave the Better Therapeutics Inc (BTTX) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended BTTX as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Better Therapeutics Inc’s EPS for the current quarter is expected to be -$0.13.
Better Therapeutics Inc (NASDAQ:BTTX) trade information
Instantly BTTX was in green as seen at the end of in last trading. With action 39.07%, the performance over the past five days has been green. The jump to weekly highs of 0.2150 on Friday, 11/17/23 added 23.60% to the stock’s daily price. The company’s shares are showing year-to-date downside of -81.00%, with the 5-day performance at 39.07% in the green. However, in the 30-day time frame, Better Therapeutics Inc (NASDAQ:BTTX) is 3.55% up. Looking at the short shares, we see there were 1.59 million shares sold at short interest cover period of 0.39 days.
The consensus price target for the stock as assigned by Wall Street analysts is $5.25, meaning bulls need an upside of 96.0% from its current market value. According to analyst projections, BTTX’s forecast low is $1.50 with $9.00 as the target high. To hit the forecast high, the stock’s price needs a -4185.71% plunge from its current level, while the stock would need to soar -614.29% for it to hit the projected low.
Better Therapeutics Inc (BTTX) estimates and forecasts
Data shows that the Better Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -74.08% over the past 6 months, a 49.11% in annual growth rate that is considerably higher than the industry average of 11.30%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Better Therapeutics Inc will rise 64.90%, while the growth in revenue is estimated to hit 56.40% for the next quarter.
The 2023 estimates are for Better Therapeutics Inc earnings to increase by 50.59%.
Better Therapeutics Inc is expected to release its next quarterly earnings report on November 09.
Better Therapeutics Inc (NASDAQ:BTTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 67.51% of Better Therapeutics Inc shares while 4.59% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 14.12%. There are 4.59% institutions holding the Better Therapeutics Inc stock share, with Vanguard Group Inc the top institutional holder. As of Jun 29, 2023, the company held 1.08% of the shares, roughly 0.44 million BTTX shares worth $0.47 million.
Farallon Capital Management Llc holds the second largest percentage of outstanding shares, with 0.81% or 0.33 million shares worth $0.36 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 0.33 million shares estimated at $0.35 million under it, the former controlled 0.80% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.28% of the shares, roughly 0.11 million shares worth around $0.12 million.